Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, Indonesia

被引:5
作者
Asih, Puji B. S. [1 ]
Rozi, Ismail E. [1 ]
Dewayanti, Farahana K. [1 ]
Wangsamuda, Suradi [1 ]
Zulfah, Syarifah [2 ]
Robaha, Marthen [3 ]
Hutahaean, Jonny [3 ]
Anggraeni, Nancy D. [4 ]
Kusumaningsih, Marti [4 ]
Mulyani, Pranti S. [4 ]
Sariwati, Elvieda [4 ]
Basri, Herdiana H. [5 ]
Bustos, Maria Dorina G. [6 ]
Syafruddin, Din [1 ,7 ]
机构
[1] Eijkman Inst Mol Biol, Malaria & Vector Resistance Unit, Jakarta, Indonesia
[2] Jambi Prov Hlth Dept, Jambi City, Jambi, Indonesia
[3] Papua Prov Hlth Dept, Jayapura City, Papua, Indonesia
[4] Minist Hlth, Malaria Sub Directorate, Jakarta, Indonesia
[5] WHO, Country Off Indonesia, Jakarta, Indonesia
[6] WHO, Country Off Thailand, Nonthaburi, Thailand
[7] Univ Hasanuddin, Fac Med, Dept Parasitol, Makasar, Indonesia
关键词
Therapeutic efficacy; Hihydroartemisinin-piperaquine (DHA-PPQ); P; falciparum; vivax; Indonesia; ARTEMISININ RESISTANCE; CAMBODIA; SPREAD;
D O I
10.1186/s12936-022-04101-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Dihydroartemisinin-piperaquine (DHA-PPQ) has been adopted as first-line therapy for uncomplicated falciparum malaria in Indonesia since 2010. The efficacy of DHA-PPQ was evaluated in 2 sentinel sites in Keerom District, Papua and Merangin District, Jambi, Sumatra from April 2017 to April 2018. Methods Clinical and parasitological parameters were monitored over a 42-day period following the World Health Organization standard in vivo protocol and subjects meeting the inclusion criteria were treated with DHA-PPQ once daily for 3 days, administered orally. Results In Papua, 6339 subjects were screened through active and passive cases detection. Of the 114 falciparum and 81 vivax cases enrolled, 102 falciparum and 80 vivax cases completed the 42 day follow up, and 12 falciparum and 1 vivax cases were either lost to follow up or withdrawn. Kaplan-Meier analysis of microscopy readings of 102 falciparum cases revealed 93.1% (95% CI 86.4-97.2) as Adequate Clinical and Parasitological Response (ACPR). No delay in parasite clearance nor severe adverse reaction was observed. Recurrent parasites of Plasmodium falciparum were detected in 7 cases and categorized as late treatment failures (LTF) at days 21, 35, and 42 and one of which was reinfected by Plasmodium vivax at day 42. Two cases were confirmed as recrudescent infection and 4 were re-infection. The PCR-corrected DHA-PPQ efficacy for P. falciparum was 97.9% (95% CI 92.7-99.7). Of the 80 cases of P. vivax that were followed up, 71 cases were completely cured and classified as ACPR (88.8%, 95% CI 79.7-94.7) and 9 cases showed recurrent infection at days 35 and 42, and classified as LTF. In Sumatra, of the 751 subjects screened, 35 vivax subjects enrolled, 34 completed the 42 day follow up. Thirty-three cases were completely cured and classified as ACPR (97.1%, 95% CI 84.7-99.9) and 1 recurrent infection was observed and classified as LTF. No delay in parasite clearance nor severe adverse reaction was observed. Analysis of the Pfk13 gene in P. falciparum cases from Papua revealed no mutations associated with artemisinin resistance in the 20 SNPs previously reported. Analysis of the Pfpm2 gene at day 0 and day of recurrence in recrudescent cases revealed the same single copy number, whereas 3 of the 4 re-infection cases carried 2-3 Pfpm2 gene copy numbers. Conclusion Treatment of falciparum and vivax malaria cases with DHA-PPQ showed a high efficacy and safety.
引用
收藏
页数:9
相关论文
共 28 条
[1]   Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study [J].
Amaratunga, Chanaki ;
Lim, Pharath ;
Suon, Seila ;
Sreng, Sokunthea ;
Mao, Sivanna ;
Sopha, Chantha ;
Sam, Baramey ;
Dek, Dalin ;
Try, Vorleak ;
Amato, Roberto ;
Blessborn, Daniel ;
Song, Lijiang ;
Tullo, Gregory S. ;
Fay, Michael P. ;
Anderson, Jennifer M. ;
Tarning, Joel ;
Fairhurst, Rick M. .
LANCET INFECTIOUS DISEASES, 2016, 16 (03) :357-365
[2]   Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening [J].
Anderle, Athena ;
Bancone, Germana ;
Domingo, Gonzalo J. ;
Gerth-Guyette, Emily ;
Pal, Sampa ;
Satyagraha, Ari W. .
INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2018, 4 (04)
[3]   A molecular marker of artemisinin-resistant Plasmodium falciparum malaria [J].
Ariey, Frederic ;
Witkowski, Benoit ;
Amaratunga, Chanaki ;
Beghain, Johann ;
Langlois, Anne-Claire ;
Khim, Nimol ;
Kim, Saorin ;
Duru, Valentine ;
Bouchier, Christiane ;
Ma, Laurence ;
Lim, Pharath ;
Leang, Rithea ;
Duong, Socheat ;
Sreng, Sokunthea ;
Suon, Seila ;
Chuor, Char Meng ;
Bout, Denis Mey ;
Menard, Sandie ;
Rogers, William O. ;
Genton, Blaise ;
Fandeur, Thierry ;
Miotto, Olivo ;
Ringwald, Pascal ;
Le Bras, Jacques ;
Berry, Antoine ;
Barale, Jean-Christophe ;
Fairhurst, Rick M. ;
Benoit-Vical, Franoise ;
Mercereau-Puijalon, Odile ;
Menard, Didier .
NATURE, 2014, 505 (7481) :50-+
[4]   Spread of Artemisinin Resistance in Plasmodium falciparum Malaria [J].
Ashley, E. A. ;
Dhorda, M. ;
Fairhurst, R. M. ;
Amaratunga, C. ;
Lim, P. ;
Suon, S. ;
Sreng, S. ;
Anderson, J. M. ;
Mao, S. ;
Sam, B. ;
Sopha, C. ;
Chuor, C. M. ;
Nguon, C. ;
Sovannaroth, S. ;
Pukrittayakamee, S. ;
Jittamala, P. ;
Chotivanich, K. ;
Chutasmit, K. ;
Suchatsoonthorn, C. ;
Runcharoen, R. ;
Hien, T. T. ;
Thuy-Nhien, N. T. ;
Thanh, N. V. ;
Phu, N. H. ;
Htut, Y. ;
Han, K-T. ;
Aye, K. H. ;
Mokuolu, O. A. ;
Olaosebikan, R. R. ;
Folaranmi, O. O. ;
Mayxay, M. ;
Khanthavong, M. ;
Hongvanthong, B. ;
Newton, P. N. ;
Onyamboko, M. A. ;
Fanello, C. I. ;
Tshefu, A. K. ;
Mishra, N. ;
Valecha, N. ;
Phyo, A. P. ;
Nosten, F. ;
Yi, P. ;
Tripura, R. ;
Borrmann, S. ;
Bashraheil, M. ;
Peshu, J. ;
Faiz, M. A. ;
Ghose, A. ;
Hossain, M. A. ;
Samad, R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (05) :411-423
[5]   Efficacy of Artemisinin-Based Combination Therapy for Treatment of Persons with Uncomplicated Plasmodium falciparum Malaria in West Sumba District, East Nusa Tenggara Province, Indonesia, and Genotypic Profiles of the Parasite [J].
Asih, Puji B. S. ;
Dewi, Rita M. ;
Tuti, Sekar ;
Sadikin, Mohamad ;
Sumarto, Wajio ;
Sinaga, Bonar ;
van der Ven, Andre J. A. M. ;
Sauerwein, Robert W. ;
Sayfruddin, Din .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 80 (06) :914-918
[6]  
Davis TME, 2005, DRUGS, V65, P75, DOI 10.2165/00003495-200565010-00004
[7]   Artemisinin Resistance in Plasmodium falciparum Malaria. [J].
Dondorp, Arjen M. ;
Nosten, Francois ;
Yi, Poravuth ;
Das, Debashish ;
Phyo, Aung Phae ;
Tarning, Joel ;
Lwin, Khin Maung ;
Ariey, Frederic ;
Hanpithakpong, Warunee ;
Lee, Sue J. ;
Ringwald, Pascal ;
Silamut, Kamolrat ;
Imwong, Mallika ;
Chotivanich, Kesinee ;
Lim, Pharath ;
Herdman, Trent ;
An, Sen Sam ;
Yeung, Shunmay ;
Singhasivanon, Pratap ;
Day, Nicholas P. J. ;
Lindegardh, Niklas ;
Socheat, Duong ;
White, Nicholas J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (05) :455-467
[8]   Dihydroartemisinin-piperaquine versus artesunate-amodiaquine:: Superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria [J].
Hasugian, A. R. ;
Purba, H. L. E. ;
Kenangalem, E. ;
Wuwung, R. M. ;
Ebsworth, E. P. ;
Maristela, R. ;
Penttinen, P. M. P. ;
Laihad, F. ;
Anstey, N. M. ;
Tjitra, E. ;
Price, R. N. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (08) :1067-1074
[9]  
Indonesia Statistical Center, 2022, BAD PUS STAT
[10]   Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment [J].
Leang, Rithea ;
Taylor, Walter R. J. ;
Bouth, Denis Mey ;
Song, Lijiang ;
Tarning, Joel ;
Char, Meng Chuor ;
Kim, Saorin ;
Witkowski, Benoit ;
Duru, Valentine ;
Domergue, Anais ;
Khim, Nimol ;
Ringwald, Pascal ;
Menard, Didier .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) :4719-4726